Medicamen Biotech Ltd
Medicamen Biotech Ltd Share Price Today: Live Updates & Key Insights
Get insights on Medicamen Biotech Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Medicamen Biotech Ltd Share Price Chart
MEDICAMEQ at 10 Jul 2026 05:36 PM Pharmaceuticals
245.35 -0.05(-0.02%)
Lowest Today 244.00
Highest Today 251.40
Today's Open 248.00
Prev. Close 245.40
52 Week High 544.00
52 Week Low 212.40
Medicamen Biotech Ltd Fundamentals
Traded Volume: 11,149
Market Cap(Cr): 332.76
Avg Traded Price 248.48
1 Year return -37.94%
Upper Circuit 251.4
Lower Circuit 244
P/E TTM 31.00
P/B Ratio 1.208
Traded Value(Cr) 27.35
EPS TTM 8.009
Book value/Share 203.170
Dividend Yield 1Y 0.41%
Medicamen Biotech Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Medicamen Biotech Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Medicamen Biotech Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W -4.44%
1M +2.34%
3M +3.55%
1Y -37.94%
YTD -35.68%
Medicamen Biotech Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Medicamen Biotech Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 26839.00
Day Before Yesterday 38660.00
1W Avg 27379.80
1M Avg 42210.52
3M Avg 33051.18
Medicamen Biotech Ltd Technical Details
Medicamen Biotech Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 242
Support 2 239
Support 3 233
Pivot Point : 248
Resistance 1 251
Resistance 2 257
Resistance 3 260
Medicamen Biotech Ltd Corporate Actions
Medicamen Biotech Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Medicamen Biotech Ltd’s capital allocation strategies.
All
Ex-Date 19-Sep-2025 Type D Description 1.00/share@10.00% Record Date 19-Sep-2025 Ratio 10.00
Ex-Date 19-Sep-2024 Type D Description 1.00/share@10.00% Record Date 19-Sep-2024 Ratio 10.00
Ex-Date 20-Sep-2023 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00
Ex-Date 19-Sep-2022 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00
Ex-Date 16-Sep-2021 Type D Description 1.00/share@10.00% Record Date - Ratio 10.00
Ex-Date 17-Sep-2020 Type D Description 0.50/share@5.00% Record Date - Ratio 5.00
Ex-Date 17-Sep-2019 Type D Description 1.00/share@10.00% Record Date 18-Sep-2019 Ratio 10.00
Ex-Date 08-Aug-2017 Type D Description 1.00/share@10.00% Record Date 09-Aug-2017 Ratio 10.00
Ex-Date 21-Sep-2010 Type D Description 0.75/share@7.50% Record Date - Ratio 7.50
Dividends
Announcement Date 19-Sep-2025 Ex Dividend Date 19-Sep-2025 Dividend(%) 10
Announcement Date 19-Sep-2024 Ex Dividend Date 19-Sep-2024 Dividend(%) 10
Announcement Date 20-Sep-2023 Ex Dividend Date 20-Sep-2023 Dividend(%) 10
Announcement Date 19-Sep-2022 Ex Dividend Date 19-Sep-2022 Dividend(%) 10
Announcement Date 16-Sep-2021 Ex Dividend Date 16-Sep-2021 Dividend(%) 10
Announcement Date 17-Sep-2020 Ex Dividend Date 17-Sep-2020 Dividend(%) 5
Announcement Date 17-Sep-2019 Ex Dividend Date 17-Sep-2019 Dividend(%) 10
Announcement Date 08-Aug-2017 Ex Dividend Date 08-Aug-2017 Dividend(%) 10
Announcement Date 21-Sep-2010 Ex Dividend Date 21-Sep-2010 Dividend(%) 8
Bonus
No Bonus has been declared by MEDICAMEQ
Splits
No Split has been declared by MEDICAMEQ
Others
Rights No Rights has been declared by MEDICAMEQ
Medicamen Biotech Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Medicamen Biotech Ltd with leading peers in the pharmaceuticals & biotechnology sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Medicamen Biotech Ltd's relative performance and valuation against major competitors.
Stock Name Albert David Ltd ₹701.00 (+0.65%) M. Cap (Cr) 4.00 1 Yr Return (%) -23.91% P/E (TTM) -267.66 PB Ratio 1.02
Stock Name Aptus Pharma Ltd ₹224.00 (+1.93%) M. Cap (Cr) 3.84 1 Yr Return (%) NaN% P/E (TTM) 83.15 PB Ratio 16.45
Stock Name Valiant Laboratories Ltd ₹62.08 (-0.13%) M. Cap (Cr) 3.37 1 Yr Return (%) -41.98% P/E (TTM) -102.91 PB Ratio 1.08
Stock Name Medicamen Biotech Ltd ₹245.35 (-0.02%) M. Cap (Cr) 3.33 1 Yr Return (%) -37.94% P/E (TTM) 30.63 PB Ratio 1.21
Stock Name Medico Remedies Ltd ₹39.71 (+1.59%) M. Cap (Cr) 3.30 1 Yr Return (%) -5.36% P/E (TTM) 25.13 PB Ratio 4.37
Stock Name Trident Lifeline Ltd ₹262.50 (-0.61%) M. Cap (Cr) 3.13 1 Yr Return (%) -2.51% P/E (TTM) 16.26 PB Ratio 3.21
Stock Name BDH Industries Ltd ₹520.00 (+0.39%) M. Cap (Cr) 3.00 1 Yr Return (%) +96.26% P/E (TTM) 27.68 PB Ratio 3.89
Medicamen Biotech Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Medicamen Biotech Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2026 -29.26 Mar 2025 -2.63 Mar 2024 -0.25 Mar 2023 -3.50 Mar 2022 4.81
PARTICULARS Investing Activities Mar 2026 -2.85 Mar 2025 -1.72 Mar 2024 -8.71 Mar 2023 -7.54 Mar 2022 -8.47
PARTICULARS Financing Activities Mar 2026 59.61 Mar 2025 -6.68 Mar 2024 3.14 Mar 2023 27.67 Mar 2022 4.39
PARTICULARS Net Cash Flow Mar 2026 27.50 Mar 2025 -11.04 Mar 2024 -5.82 Mar 2023 16.63 Mar 2022 0.73
Medicamen Biotech Ltd Shareholding Pattern
This shows the ownership breakdown of Medicamen Biotech Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 40.46%
Public 59.39%
Other Institutions 0.05%
FII 0.1%
Mutual Funds N/A%
About Medicamen Biotech Ltd
A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets. The Company has presence over 35+ countries. Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market. MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan). The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.The Bhiwadi unit has ultra modern production facilities incorporating latest state of the art technology with a combination of technically qualified personnel and hardworking workforce. In Haridwar unit, the company manufactures Non-Betalactum preparations including tablets, capsules, oral liquids and ointments & creams.Medicamen Biotech Limited was incorporated in December, 1993 and started their operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries.The vast distribution network with demand for low cost medicines prompted the company to go for own manufacturing facilities. Thus, in the year 1994, a land of 210,000 square feet in the Industrial town of Bhiwadi in the state of Rajasthan was procured. In the year 1995, the company was enlisted in Bombay Stock Exchange.In the year 2005, the company installed the second unit in the tax free zone at Haridwar in Uttarakhand, keeping the space with the ever increase in demand and fulfilling the commitment.During the year 2006-07, the company added Analgesic and Anti bacterial, Anti filarial and Anti TB products in its range and done two mega projects of Govt. of India related to Anti filarial and Anti TB drugs. They also supplied Anti bacterial products like Cotrimoxazole and Anti Analgesics like Paracetamol in bulk to their foreign partners. During the year, the company increased the production capacity of Tablets by 600 lakh Nos to 7800 lakh Nos.The second unit in Haridwar became fully operational from April 2007 with ultra modern manufacturing facilities comprises of Non Betalactum Tablets, Capsules, oral liquids & ointments with the production capacity of 4100 lakh Nos, 600 lakh Nos, 6 lakh Litre and 0.30 lakh kg respectively. The company upgraded the Bhiwadi unit with a consolidated cost of more than Rs 2.5 crore under the latest WHO guidelines on CGMP.'The Company launched the marketing division in Jan'09, with 16 products in Delhi & Uttrakhand regions. On September 16, 2015, M/s. Shivalik Rasayan Limited (Acquirer) got into two Share Purchase Agreements(SPAs) with Promoters of the Company - SPA 1 with Mr. Bal Kishan Gupta, Mr. Ashutosh Gupta, Ms. Ritu Gupta, Ms. Suchita Gupta and SPA 2 with Mr. Abhishek Bansal, Ms. Manju Bansal, Mr. Sanjay Bansal and Ms. Ayushi Bansal for the acquisition of 44,12,095 fully paid-up Equity Shares of Rs.10/- each representing 44.15% of the paid up equity share capital of the Company through which the Acquirer made a Takeover Open Offer Transaction to acquire 26% of the Paid up Capital of the Company, which was completed in December, 2015 and the Acquirer became New Promoter of the Company.The Company acquired 100% stake of OPAL Pharmaceuticals Pty Ltd from its existing shareholder aggregating upto (AUD) $4,20,000 in 2019-20. OPAL, a wholly owned subsidiary of the Company, merged with the Company effective September 17, 2019. The Company launched 12 Oncology products in domestic market w.e.f. January, 2022.The Company's Bhiwadi Manufacturing Facility achieved European Union GMP Approval from MOH, Greece in FY25.
Chairman & Non Executive Dir.
Rahul Bishnoi
Registered office 1506 Chiranjiv Tower 43, Nehru Place, New Delhi, New Delhi, 110019
FAX :91-11-47589500
Background
Incorporation Year 1993
Face Value ₹10.00
Market Lot 1
FAQs on Medicamen Biotech Ltd
How to buy Medicamen Biotech Ltd shares?
To buy Medicamen Biotech Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the market cap of Medicamen Biotech Ltd?
The company has a market capitalization of ₹332.76.
What is the PE & PB ratio of Medicamen Biotech Ltd?
PE is 31 and PB is 1.208.
What is the Medicamen Biotech Ltd dividend for 2025–26?
For the 2025–26 financial year, Medicamen Biotech Ltd declared a final dividend of 0.41% per share.